Increased Glutamate/Glutamine Compounds in the Brains of Patients With Fibromyalgia A Magnetic Resonance Spectroscopy Study

Institut d'Investigacions Biomèdiques August Pi i Sunyer and Hospital Clínic of Barcelona, Barcelona, Spain.
Arthritis & Rheumatology (Impact Factor: 7.87). 06/2010; 62(6):1829-36. DOI: 10.1002/art.27430
Source: PubMed

ABSTRACT Fibromyalgia (FM) has been defined as a systemic disorder that is clinically characterized by pain, cognitive deficit, and the presence of associated psychopathology, all of which are suggestive of a primary brain dysfunction. This study was undertaken to identify the nature of this cerebral dysfunction by assessing the brain metabolite patterns in patients with FM through magnetic resonance spectroscopy (MRS) techniques.
A cohort of 28 female patients with FM and a control group of 24 healthy women of the same age were studied. MRS techniques were used to study brain metabolites in the amygdala, thalami, and prefrontal cortex of these women.
In comparison with healthy controls, patients with FM showed higher levels of glutamate/glutamine (Glx) compounds (mean +/- SD 11.9 +/- 1.6 arbitrary units [AU] versus 13.4 +/- 1.7 AU in controls and patients, respectively; t = 2.517, 35 df, corrected P = 0.03) and a higher Glx:creatine ratio (mean +/- SD 2.1 +/- 0.4 versus 2.4 +/- 1.4, respectively; t = 2.373, 35 df, corrected P = 0.04) in the right amygdala. In FM patients with increased levels of pain intensity, greater fatigue, and more symptoms of depression, inositol levels in the right amygdala and right thalamus were significantly higher.
The distinctive metabolic features found in the right amygdala of patients with FM suggest the possible existence of a neural dysfunction in emotional processing. The results appear to extend previous findings regarding the dysfunction in pain processing observed in patients with FM.

Download full-text


Available from: Nuria Bargalló, Oct 13, 2014
1 Follower
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Fibromyalgia (FM) is a prevalent and disabling chronic disease. Recent studies have found elevated levels of glutamate in several brain regions, leading to hypotheses about the usefulness of glutamate blocking drugs such as memantine in the treatment of FM. The aim of this study is to evaluate the efficacy of memantine in the treatment of pain and other clinical variables (global function, clinical impression, depression, anxiety, quality of life) in FM patients. Trial Design: A double-blind parallel randomised controlled trial was developed. A total of 63 patients diagnosed with FM were recruited from primary health care centres in Zaragoza, Spain. Memantine was administered at doses of 20 mg/day after one month of titration. Assessments were carried out at baseline, post-treatment, and 3- and 6-month follow-ups. Compared with a placebo group, memantine significantly decreased ratings on a pain visual analogue scale (Cohen's d=1.43 at 6 months) and pain measured with a sphygmomanometer (d=1.05). All other secondary outcomes except anxiety also improved, with moderate-to-large effect sizes at 6 months. Compared to placebo, the absolute risk reduction obtained with memantine was 16.13% (95% CI=2.0-32.6%), and the number needed to treat (NNT) was 6.2 (95% CI=3-47). Tolerance was good, with dizziness (8 patients) and headache (4 patients) being the most frequent side effects of memantine. Although additional studies with larger samples and longer follow-ups are needed, this study provides preliminary evidence of the utility of memantine for the treatment of FM.
    Pain 09/2014; 155(12). DOI:10.1016/j.pain.2014.09.004 · 5.84 Impact Factor
  • Source
    New Insights into Fibromyalgia, 01/2012; , ISBN: 978-953-307-407-8
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Fibromyalgia is considered a stress-related disorder, and hypo- as well as hyperactive stress systems (sympathetic nervous system and hypothalamic-pituitary-adrenal axis) have been found. Some observations raise doubts on the view that alterations in these stress systems are solely responsible for fibromyalgia symptoms. Cumulative evidence points at dysfunctional transmitter systems that may underlie the major symptoms of the condition. In addition, all transmitter systems found to be altered in fibromyalgia influence the body's stress systems. Since both transmitter and stress systems change during chronic stress, it is conceivable that both systems change in parallel, interact, and contribute to the phenotype of fibromyalgia. As we outline in this paper, subgroups of patients might exhibit varying degrees and types of transmitter dysfunction, explaining differences in symptomatoloy and contributing to the heterogeneity of fibromyalgia. The finding that not all fibromyalgia patients respond to the same medications, targeting dysfunctional transmitter systems, further supports this hypothesis.
    01/2012; 2012(2090-1542):741746. DOI:10.1155/2012/741746